Risk factors for deterioration of long-term liver function after radiofrequency ablation therapy

Abstract

AIM:To identify factors that influence long-term liver function following radiofrequency ablation (RFA) in patients with viral hepatitis-related hepatocellular carcinoma. METHODS:A total of 123 patients with hepatitis B virus-or hepatitis C virus-related hepatocellular carcinoma (HCC) (n = 12 and n = 111, respectively) were enrolled. Cumulative rates of worsening Child-Pugh (CP) scores (defined as a 2-point increase) were examined. RESULTS:CP score worsening was confirmed in 22 patients over a mean follow-up period of 43.8 ± 26.3 mo. Multivariate analysis identified CP class, platelet count, and aspartate aminotransferase levels as significant predictors of a worsening CP score (P = 0.000, P = 0.011 and P = 0.024, respectively). In contrast, repeated RFA was not identified as a risk factor for liver function deterioration. CONCLUSION:Long-term liver function following RFA was dependent on liver functional reserve, the degree Risk factors for deterioration of long-term liver function after radiofrequency ablation therapy Retrospective Cohort Study ORIGINAL ARTICLEof fibrosis present, and the activity of the hepatitis condition for this cohort. Therefore, in order to maintain liver function for an extended period following RFA, suppression of viral hepatitis activity is important even after the treatment of HCC. Core tip: This study was conducted to identify risk factors for liver function deterioration following radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC) and viral hepatitis. A total of 123 patients with hepatitis B virus-or hepatitis C virusrelated HCC were enrolled. Cumulative rates of worsening Child-Pugh (CP) scores (defined as a 2-point increase) following RFA were examined. CP class, platelet count, and aspartate aminotransferase levels were identified as significant predictors of a worsening CP score. Suppression of viral hepatitis activity with anti-viral therapy is important even after the treatment of HCC in order to maintain liver function following RFA.

Impact of Radiofrequency Ablation-Induced Glisson’s Capsule-Associated Complications in Patients with Hepatocellular Carcinoma

“…The median maximum tumor size was 19 mm (range, 6.5–42 mm), and 129 patients (75.9%) had a single tumor. One hundred and fifty-two patients were Child—Pugh A (89.4%) and the remaining were Child—Pugh B. Tumor size and liver function were similar to data in recent studies from Japan [14,15]. Procedural rate for HCC treatment was 1.35 (one procedure: 110 patients; two procedures: 60 patients).…”